Jazz Pharmaceuticals and AbCellera announce a collaboration to discover next-generation T-cell engaging multispecific antibody therapies. Under the agreement, AbCellera receives an upfront payment of $56 million. The companies also outline additional payments that could be triggered as programs advance, including up to $792 million in option fees and milestone payments if Jazz exercises its options to develop specific antibody programs.
The terms give Jazz an exclusive option to develop and commercialize therapeutic antibodies resulting from the collaboration. Both outlets describe the same overall structure: discovery work conducted through the partnership, a financial package tied to Jazz’s exercise of development rights, and potential further compensation for reaching milestones.
The announcement is presented as a biotech deal focused on generating therapeutic antibody candidates that engage T cells using a multispecific approach, with Jazz holding the decision points to move candidates forward for development and commercialization. No additional clinical results or trial data are included in the reported summaries.
